Daw Stephen, Hasenclever Dirk, Mascarin Maurizio, Fernández-Teijeiro Ana, Balwierz Walentyna, Beishuizen Auke, Burnelli Roberta, Cepelova Michaela, Claviez Alexander, Dieckmann Karin, Landman-Parker Judith, Kluge Regine, Körholz Dieter, Mauz-Körholz Christine, Wallace William Hamish, Leblanc Thierry
Children and Young People's Cancer Services, University College Hospital London, London, UK.
Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Hemasphere. 2020 Jan 10;4(1):e329. doi: 10.1097/HS9.0000000000000329. eCollection 2020 Feb.
The objective of this guideline is to aid clinicians in making individual salvage treatment plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical Hodgkin lymphoma (cHL). While salvage with standard dose chemotherapy followed by high dose chemotherapy and autologous stem cell transplant is often considered the standard of care in adult practice, pediatric practice adopts a more individualized risk stratified and response adapted approach to salvage treatment with greater use of non-transplant salvage. Here, we present on behalf of the EuroNet Pediatric Hodgkin Lymphoma group, evidence and consensus-based guidelines for standardized diagnostic, prognostic and response procedures to allocate children and adolescents with R/R cHL to stratified salvage treatments.
本指南的目的是帮助临床医生为首次复发或难治性(R/R)经典霍奇金淋巴瘤(cHL)的儿科和青少年患者制定个体化的挽救治疗方案。虽然在成人实践中,标准剂量化疗后进行高剂量化疗和自体干细胞移植的挽救治疗通常被视为标准治疗方法,但儿科实践采用更个体化的风险分层和基于反应的方法进行挽救治疗,更多地使用非移植挽救治疗。在此,我们代表欧洲儿童霍奇金淋巴瘤网络组,提出基于证据和共识的标准化诊断、预后和反应程序指南,以便将R/R cHL儿童和青少年患者分配到分层挽救治疗中。